文章摘要
印卫锋,陈苏,李文凯,等.硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎的临床研究.骨科,2016,7(3): 190-194.
硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎的临床研究
Clinical research of glucosamine sulfate combined with etoricoxib for the treatment of knee osteoarthritis
投稿时间:2016-02-29  
DOI:DOI:10.3969/j.issn.1674-8573.2016.03.011
中文关键词: 骨关节炎,膝  药物疗法,联合  依托考昔  硫酸氨基葡萄糖
英文关键词: Osteoarthritis, knee  Drug therapy, combination  Etoricoxib  Glucosamine sulfate
基金项目:国家自然科学基金(31070831)
作者单位E-mail
印卫锋 430030 武汉华中科技大学同济医学院附属同济医院骨科  
陈苏 华中科技大学同济医学院附属同济医院甲乳外科  
李文凯 430030 武汉华中科技大学同济医学院附属同济医院骨科  
李兴艳 430030 武汉华中科技大学同济医学院附属同济医院骨科  
郭风劲 430030 武汉华中科技大学同济医学院附属同济医院骨科  
张伟凯 430030 武汉华中科技大学同济医学院附属同济医院骨科 wk-zhang@hotmail.com 
摘要点击次数: 5247
全文下载次数: 0
中文摘要:
      目的 研究硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎的疗效以及安全性。方法 将2013年9月至2014年9月于我院骨科门诊确诊为膝关节骨性关节炎的150例患者按随机数字表法分成依托考昔组、硫酸氨基葡萄糖组和联合组,每组50例,分别给予依托考昔、硫酸氨基葡萄糖、两种药物联合用药治疗6周。于用药2周和6周时采用西安大略和麦克马斯特大学(the Western Ontario and McMaster Universities, WOMAC)骨关节炎指数评估疗效并观察不良反应。结果 11例因不良反应退出试验,6例失访,最终133例完成试验且随访资料完整,其中依托考昔组44例,硫酸氨基葡萄糖组43例,联合组46例。治疗2周后,依托考昔组和联合组的WOMAC指数较治疗前有显著改善,其中联合组的改善优于依托考昔组(P<0.05);依托考昔组、硫酸氨基葡萄糖组、联合组的不良反应例数分别为2例、1例和2例。治疗6周后,3组患者的WOMAC指数均优于治疗前(均P<0.05),其中联合组优于依托考昔组和硫酸氨基葡萄糖组(P<0.05),硫酸氨基葡萄糖组优于依托考昔组(P<0.05);3组各发生2例不良反应。结论 硫酸氨基葡萄糖联合依托考昔治疗膝关节骨性关节炎比单独使用依托考昔或硫酸氨基葡萄糖的疗效好、起效快,值得临床推广。
英文摘要:
      Objective To study the effectiveness and security of glucosamine sulfate combined with etoricoxib in the treatment of knee osteoarthritis. Methods Cases of 150 patients with knee osteoarthritis in Orthopaedic Clinic of our hospital from September 2013 to September 2014 were randomly divided into 3 groups in accordance with the random number table. The patients in each group were treated with different drugs for 6 weeks and followed up at 2nd and 6th week, respectively. The etoricoxib group was administered orally with etoricoxib, glucosamine sulfate group was given orally with glucosamine sulfate, and combination group was given orally with etoricoxib and glucosamine sulfate. Western Ontario and McMaster Universities (WOMAC) osteoarthritis index was used to evaluate the effectiveness. Adverse reactions during the treatment were recorded. Results Eleven patients withdrew from the study due to adverse reactions, 6 cases were lost, and 133 cases completed the test and had complete follow-up data, including 44 cases in etoricoxib group, 43 cases in glucosamine sulfate group, and 46 cases in combination group. After 2 weeks, effectiveness of both etoricoxib group and combination group were more satisfactfory than that pre-treatment (P<0.05), whereas glucosamine sulfate group had no improvement compared to pre-treatment (P>0.05). Effectiveness in combination group was more satisfactory than etoricoxib group (P<0.05). Adverse reactions occurred in 5 cases. After 6 weeks of treatment, effectiveness in all 3 groups were significantly better than that of pre-treatment (P<0.05). Effectiveness in combination group was significantly better than that in etoricoxib group and glucosamine sulfate group (P<0.05), and effectiveness in glucosamine group was better than that in etoricoxib group (P<0.05). Six cases of adverse reactions were recorded. Conclusion Glucosamine sulfate combined with etoricoxib shows excellent curative effects on knee osteoarthritis with rapid relief and good security than etoricoxibor or glucosamine sulfate used alone, and worthwhile for spreading in clinical practice.
查看全文   下载PDF阅读器
关闭